Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit

BACKGROUND: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Triulzi, Tiziana, Regondi, Viola, De Cecco, Loris, Cappelletti, Maria Rosa, Di Modica, Martina, Paolini, Biagio, Lollini, Pier Luigi, Di Cosimo, Serena, Sfondrini, Lucia, Generali, Daniele, Tagliabue, Elda
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6288086/
https://ncbi.nlm.nih.gov/pubmed/30478407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0318-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados